Skip to main content
RDHL
NASDAQ Life Sciences

RedHill Biopharma Registers Resale of 26.2M ADSs from Private Placement, Signaling Massive Potential Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.69
Mkt Cap
$4.214M
52W Low
$0.637
52W High
$3.31
52W Position info
8.3% above low
Off High info
79% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

RDHL is trading near its 52-week low of $0.637 (8.3% above the low).

Summary

RedHill Biopharma has filed to register the resale of up to 26.2 million ADSs by selling shareholders, stemming from a June 2026 private placement, which represents over 400% potential dilution to current outstanding shares.


Key Events · Financing and Capital Events · RDHL

  • Resale Registration Filed

    RedHill Biopharma has registered up to 26,228,573 American Depositary Shares (ADSs) for resale by selling shareholders.

  • Massive Potential Dilution

    The registered ADSs represent over 431% of the currently outstanding 6,080,920 ADSs, indicating significant potential dilution if all are sold.

  • Conditional Proceeds to Company

    The company could receive up to $13.8 million if all underlying warrants are exercised for cash, but notes that many warrants are currently out-of-the-money, making substantial cash proceeds uncertain.

  • Origin of Securities

    The ADSs are issuable upon exercise of warrants issued in a private placement dated June 18, 2026, which was previously announced.


Analysis · RDHL · Life Sciences

This filing formalizes the ability for investors from a June 2026 private placement to resell up to 26.2 million ADSs, which could lead to massive dilution for existing shareholders. While the company could receive up to $13.8 million if all underlying warrants are exercised, many are currently out-of-the-money, making significant cash proceeds uncertain. This potential influx of shares into the market, combined with the company's ongoing Nasdaq delisting warnings and micro-cap status, creates a substantial overhang and significant risk for investors.

At the time of this filing, RDHL was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.64 to $3.31. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RDHL - Latest Insights

RDHL
Jul 14, 2026, 6:00 AM EDT
Filing Type: 424B3
Importance Score:
9
RDHL
Jul 02, 2026, 7:32 AM EDT
Filing Type: F-3
Importance Score:
8
RDHL
Jun 29, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
9
RDHL
Jun 29, 2026, 7:00 AM EDT
Filing Type: 424B5
Importance Score:
9
RDHL
Jun 22, 2026, 4:21 PM EDT
Filing Type: 6-K
Importance Score:
9
RDHL
Jun 22, 2026, 4:10 PM EDT
Source: PR Newswire
Importance Score:
9
RDHL
Jun 22, 2026, 4:00 PM EDT
Filing Type: 6-K
Importance Score:
9
RDHL
Jun 22, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
RDHL
Jun 18, 2026, 8:03 AM EDT
Filing Type: 6-K
Importance Score:
9
RDHL
Jun 18, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9